Indivior Share Discussion Threads

[amaretto1] 08/4/2020 11:41

im out talked to my guru
she says sell veiled profits warning
sorry did have faith
invested else were, good look longs
cx4d far morew potencial lost 20k for now.

[the stigologist] 08/4/2020 09:16

Just highlights the now massive game changing importance of C4XD Orexin antagonist INDV2000 to future of INDV now

From a Lawsuit perspective it's a nice cheeky : "hey even if you win we might already be bankrupt"

DoJ might say do we want to risk wiping out INDV employees during a Recession / Plague ?

Clever.

[amaretto1] 08/4/2020 07:40

Only inline with every other company, doing the sameWhat do we expect with lock down all around the world.

[waldron] 07/4/2020 14:12

not recent but perhaps worth another read




Auditors Are Concerned About Indivior (LON:INDV)
Simply Wall St March 18, 2020

The harsh reality for Indivior PLC (LON:INDV) shareholders is that its auditors, PricewaterhouseCoopers LLP, expressed doubts about its ability to continue as a going concern, in its reported results to December 2019. Thus we can say that, based on the results to that date, the company should raise capital or otherwise raise cash, without much delay.

If the company does have to issue more shares, potential investors will be sure to consider how desperate it is for capital. So current risks on the balance sheet could have a big impact on how shareholders fare from here. Debt is always a risk factor in these cases, as creditors could be in a position to wind up the company, in the worst case scenario.

See our latest analysis for Indivior
What Is Indivior’s Net Debt?


How Strong Is Indivior’s Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Indivior had liabilities of US$742.0m due within 12 months and liabilities of US$701.0m due beyond that. Offsetting these obligations, it had cash of US$1.06b as well as receivables valued at US$204.0m due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by US$179.0m.

This deficit isn’t so bad because Indivior is worth US$366.4m, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. But it’s clear that we should definitely closely examine whether it can manage its debt without dilution. Despite its noteworthy liabilities, Indivior boasts net cash, so it’s fair to say it does not have a heavy debt load!

It is just as well that Indivior’s load is not too heavy, because its EBIT was down 39% over the last year. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately the future profitability of the business will decide if Indivior can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. While Indivior has net cash on its balance sheet, it’s still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. During the last three years, Indivior generated free cash flow amounting to a very robust 96% of its EBIT, more than we’d expect. That puts it in a very strong position to pay down debt.
Summing up

Although Indivior’s balance sheet isn’t particularly strong, due to the total liabilities, it is clearly positive to see that it has net cash of US$823.0m. The cherry on top was that in converted 96% of that EBIT to free cash flow, bringing in US$148m. So we are not troubled with Indivior’s debt use. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet – far from it. Like risks, for instance. Every company has them, and we’ve spotted 4 warning signs for Indivior (of which 1 can’t be ignored!) you should know about.

I

[misca2] 07/4/2020 12:02

No real news yet it continues to jump up and down like a yo yo


Price (GBX) 47.98 Var % (+/-) +7.97% (Up +3.54)

High 47.98 Low 43.58

Volume 2,612,573 Last close 44.44 on 06-Apr-2020

Bid 47.46 Offer 47.98

Trading status Regular Trading Special conditions NONE

[wossupsa] 05/4/2020 02:19

China will be picking up most of that tab buywell3, especially if Trump wins in November. The Chinese government have to pay the price for their deceit which has caused so much death and financial devastation around the world. The claim about the monies to be retrieved from Pharma's is quite laughable, the amounts are now so insignificant it's a pathetic point.

[amaretto1] 04/4/2020 10:57

Perfect chart 75 p !

[steeplejack] 03/4/2020 08:10

Your guess is as good as mine.

[buywell3] 03/4/2020 05:46

The USA is going to pump over $10 Trillion into their economy and more before this gets done , maybe even up to their GDP if needed circa $18 Trillion

Does anyone here really think they are going to walk away from getting any monies they can from court cases V foreign companies ?

[the stigologist] 03/4/2020 05:35

Any such approach would be seen as opportunistic

You'd be buying a contingent liability

Most people would think you were mad

Not a great look the CEO of a predator company being sectioned

[amaretto1] 03/4/2020 05:20

If i was big pharma .. I'd take a gamble and buy it now ! Offer 100 pence .. but I'm not :-)

[amaretto1] 03/4/2020 05:18

No such thing has potencial debt ! Net cash is as stated below.

[amaretto1] 03/4/2020 05:17

Net cash is 850 million dollars .. Cannot see any other liability's NET cash is near 1 billion !

[waldron] 02/4/2020 21:54

CHEERS STIG

[the stigologist] 02/4/2020 21:52

Anyway I went back and watched INDV recent results webcast. They expect INDV2000 trial to start in Q2 so we should get news relating to that soon

Quite clear it is the BIGGIE in their development pipeline

[waldron] 02/4/2020 17:03

Price (GBX) 43.00 Var % (+/-) -1.51% (Down -0.66)
High 44.46 Low 38.76
Volume 8,103,542 Last close 43.00 on 02-Apr-2020
Bid 43.10 Offer 43.36
Trading status Post-Close Special conditions NONE

[steeplejack] 02/4/2020 12:09

On that we are agreed!